Health Economics›Nasopharyngeal carcinoma›Recurrent or metastatic disease

Recurrent or metastatic disease

Nasopharyngeal carcinoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-TPC Variant #01	—	R 33 566	21d	~11.3 mo	—	~35	~R 231 518 PFS proxy · indirect	1
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	~7.4 mo	~27.9 mo	~6	~R 23 595 PFS proxy · indirect	8
Cisplatin and Gemcitabine (GC) and Toripalimab Variant #01 Partial	—	R 3 785	21d	~16.6 mo	—	~3	~R 11 356 PFS proxy · indirect	4
Cisplatin and Gemcitabine (GC) and Camrelizumab Variant #01 Partial	—	R 3 785	21d	9.7 mo	—	35	R 22 713 PFS proxy	1
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	~15.3 mo	~10	~R 29 215 PFS proxy · indirect	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	~15.3 mo	~7	~R 11 705 PFS proxy · indirect	1
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 235	28d	~20.1 mo	~18.6 mo	~3	~R 3 706 PFS proxy · indirect	3
Capecitabine monotherapy Variant #01	—	R 1 039	21d	~35.9 mo	~15.3 mo	~8	~R 8 309 PFS proxy · indirect	2
Toripalimab monotherapy Variant #01 Partial	—	—	14d	—	—	~11	—	—

9 of 9 regimens shown